Stemline Therapeutics Inc (STML) Expected to Announce Quarterly Sales of $7.92 Million
Wall Street analysts expect that Stemline Therapeutics Inc (NASDAQ:STML) will report $7.92 million in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Stemline Therapeutics’ earnings, with estimates ranging from $5.55 million to $11.00 million. Stemline Therapeutics reported sales of $500,000.00 during the same quarter last year, which indicates a positive year over year growth rate of 1,484%. The company is scheduled to report its next earnings results on Thursday, August 8th.
On average, analysts expect that Stemline Therapeutics will report full-year sales of $38.97 million for the current year, with estimates ranging from $23.80 million to $54.38 million. For the next financial year, analysts expect that the business will report sales of $134.20 million, with estimates ranging from $87.36 million to $207.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Stemline Therapeutics.
Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The business had revenue of $5.05 million for the quarter, compared to the consensus estimate of $2.61 million.
STML traded up $0.03 during trading on Wednesday, hitting $15.13. The stock had a trading volume of 390,160 shares, compared to its average volume of 672,671. The company has a market cap of $659.64 million, a price-to-earnings ratio of -5.06 and a beta of 1.20. Stemline Therapeutics has a twelve month low of $7.82 and a twelve month high of $20.55. The company has a quick ratio of 2.97, a current ratio of 5.07 and a debt-to-equity ratio of 0.01.
In other news, COO Kenneth Hoberman sold 10,557 shares of Stemline Therapeutics stock in a transaction on Monday, February 25th. The shares were sold at an average price of $12.05, for a total transaction of $127,211.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Ivan Bergstein sold 55,073 shares of Stemline Therapeutics stock in a transaction on Monday, March 11th. The stock was sold at an average price of $11.11, for a total transaction of $611,861.03. The disclosure for this sale can be found here. Insiders have sold 172,684 shares of company stock valued at $2,042,054 over the last quarter. Insiders own 14.80% of the company’s stock.
Large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Stemline Therapeutics during the first quarter worth $36,000. Great West Life Assurance Co. Can acquired a new stake in shares of Stemline Therapeutics during the fourth quarter worth $47,000. Legal & General Group Plc lifted its stake in shares of Stemline Therapeutics by 27.1% during the fourth quarter. Legal & General Group Plc now owns 5,249 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 1,120 shares during the period. BNP Paribas Arbitrage SA acquired a new position in Stemline Therapeutics during the first quarter valued at $102,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in Stemline Therapeutics by 327.0% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,523 shares of the biopharmaceutical company’s stock valued at $81,000 after purchasing an additional 6,527 shares during the period. Institutional investors and hedge funds own 48.38% of the company’s stock.
About Stemline Therapeutics
Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.
Read More: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.